HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

AuthorsJipan Xie, Melissa Diener, Rachael Sorg, Eric Q Wu, Madhav Namjoshi
JournalJournal of medical economics (J Med Econ) Vol. 16 Issue 2 Pg. 260-2 ( 2013) ISSN: 1941-837X [Electronic] England
PMID23176287 (Publication Type: Letter, Comment)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
Topics
  • Antibodies, Monoclonal, Humanized (economics)
  • Bone Density Conservation Agents (economics)
  • Bone Neoplasms (drug therapy)
  • Breast Neoplasms (drug therapy)
  • Carcinoma, Non-Small-Cell Lung (drug therapy)
  • Diphosphonates (economics)
  • Female
  • Humans
  • Imidazoles (economics)
  • Male
  • Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: